Rat Plasma Lipoprotein Inhibitors of Lymphocyte Proliferation: Specific Membrane Receptor for Very Low Density Lipoproteins

1981 ◽  
Vol 65 (1) ◽  
pp. 8-14 ◽  
Author(s):  
P.I. Yi ◽  
G. Beck ◽  
S. Zucker
Keyword(s):  
Lymphocyte Proliferation ◽  
Rat Plasma ◽  
Low Density Lipoproteins ◽  
Plasma Lipoprotein ◽  
Membrane Receptor ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Specific Membrane ◽  
Specific Membrane Receptor

Comparison of two micromethods for determination of lipoprotein cholesterol in plasma.

1979 ◽  
Vol 25 (10) ◽  
pp. 1795-1798 ◽  
Author(s):  
I R Kupke ◽  
S Zeugner ◽  
A Gottschalk
Keyword(s):  
Population Sample ◽  
Low Density Lipoproteins ◽  
High Density ◽  
Plasma Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
High Density Lipoproteins ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Long Distance

Abstract We compared the results obtained by a micromethod for the determination of plasma lipoprotein cholesterol, in which electrophoresis is used to separate the lipoprotein fractions (beta-, pre-beta-, and alpha-lipoproteins), with those determinations with ultracentrifugation (low-density, very-low-density, and high-density lipoproteins). Precision of determination (coefficient of variation, CV, %) was the same for beta- and low-density lipoproteins (1.6%), and for pre-beta- and very-low-density lipoproteins (3.7%); however, determination of alpha-lipoprotein cholesterol was more precise (1.4%) than that of high-density lipoprotein cholesterol (3.1%). Analytical recovery of lipoprotein cholesterol was the same for both methods (98--100%) and the results were closely correlated (r = 0.943). The procedure has been used to determine the cholesterol content of plasma lipoprotein fractions of apparently healthy adults (both sexes). Lipoprotein cholesterol concentrations in our population sample compare well with those reported for other groups of similar age, in particular Stanford long-distance runners.

scholarly journals Membrane receptors for very low density lipoprotein (VLDL) inhibitor of lymphocyte proliferation

Blood ◽  
1981 ◽  
Vol 57 (6) ◽  
pp. 1055-1064 ◽  
Author(s):  
PI Yi ◽  
G Beck ◽  
S Zucker
Keyword(s):  
Dna Synthesis ◽  
Lymphocyte Proliferation ◽  
Human Lymphocytes ◽  
Low Density Lipoproteins ◽  
Membrane Receptors ◽  
Plasma Lipoproteins ◽  
High Density Lipoproteins ◽  
Scatchard Analysis ◽  
Low Density ◽  
Very Low Density Lipoproteins

Abstract Physiologic concentrations of human plasma very low density lipoproteins inhibit the DNA synthesis of lymphocytes stimulated by allogeneic cells or lectins. In this report we have compared the effects of isolated lipoproteins [very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL)] and lipoprotein-depleted plasma (LDP) on DNA synthesis by phytohemagglutinin-stimulated human lymphocytes. The relative potency for the inhibition of lymphocyte proliferation was VLDL greater than LDL greater than HDL greater than LDP. Fifty percent inhibition of DNA synthesis was observed at a VLDL protein concentration of 1.5--2.0 microgram/ml. We have further demonstrated the presence of specific receptors for VLDL on human lymphocytes. Native VLDL was more effective than LDL in competing for 125I-VLDL binding sites. Subsequent to binding to lymphocytes, 125I-VLDL was internalized and degraded to acid- soluble products. Based on a Scatchard analysis of VLDL binding at 4 degrees C, the number of VLDL receptors per lymphocyte was estimated at 28,000 +/- 1300. Based on an estimated mean binding affinity for the VLDL receptor complex at half saturation of approximately 8.8 X 10(7) liter/mole, it is estimated that 91% of lymphocyte VLDL receptors are occupied at physiologic VLDL concentrations in blood. Although the immune regulatory role of plasma lipoproteins is uncertain, we suggest tha VLDL and LDL-In may maintain circulating blood lymphocytes in a nonproliferative state via their respective cell receptor mechanisms.

scholarly journals Membrane receptors for very low density lipoprotein (VLDL) inhibitor of lymphocyte proliferation

Blood ◽  
1981 ◽  
Vol 57 (6) ◽  
pp. 1055-1064
Author(s):  
PI Yi ◽  
G Beck ◽  
S Zucker
Keyword(s):  
Dna Synthesis ◽  
Lymphocyte Proliferation ◽  
Human Lymphocytes ◽  
Low Density Lipoproteins ◽  
Membrane Receptors ◽  
Plasma Lipoproteins ◽  
High Density Lipoproteins ◽  
Scatchard Analysis ◽  
Low Density ◽  
Very Low Density Lipoproteins

Physiologic concentrations of human plasma very low density lipoproteins inhibit the DNA synthesis of lymphocytes stimulated by allogeneic cells or lectins. In this report we have compared the effects of isolated lipoproteins [very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL)] and lipoprotein-depleted plasma (LDP) on DNA synthesis by phytohemagglutinin-stimulated human lymphocytes. The relative potency for the inhibition of lymphocyte proliferation was VLDL greater than LDL greater than HDL greater than LDP. Fifty percent inhibition of DNA synthesis was observed at a VLDL protein concentration of 1.5--2.0 microgram/ml. We have further demonstrated the presence of specific receptors for VLDL on human lymphocytes. Native VLDL was more effective than LDL in competing for 125I-VLDL binding sites. Subsequent to binding to lymphocytes, 125I-VLDL was internalized and degraded to acid- soluble products. Based on a Scatchard analysis of VLDL binding at 4 degrees C, the number of VLDL receptors per lymphocyte was estimated at 28,000 +/- 1300. Based on an estimated mean binding affinity for the VLDL receptor complex at half saturation of approximately 8.8 X 10(7) liter/mole, it is estimated that 91% of lymphocyte VLDL receptors are occupied at physiologic VLDL concentrations in blood. Although the immune regulatory role of plasma lipoproteins is uncertain, we suggest tha VLDL and LDL-In may maintain circulating blood lymphocytes in a nonproliferative state via their respective cell receptor mechanisms.

Variability in Plasma Lipoprotein Profiles When Comparing Diltiazem and Propranolol

1993 ◽  
Vol 27 (9) ◽  
pp. 1048-1052
Author(s):  
Dustan G. Labreche ◽  
George T. Kondos ◽  
David W. Bartels ◽  
Jerry L. Bauman
Keyword(s):  
Drug Treatment ◽  
Comparative Trial ◽  
Low Density Lipoproteins ◽  
Plasma Lipoprotein ◽  
Plasma Lipoproteins ◽  
High Density Lipoproteins ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Double Blind ◽  
Propranolol Group

OBJECTIVE: To examine the effects of diltiazem and propranolol on plasma lipoproteins in a double-blind, comparative trial. PATIENTS: Twenty-one mild-to-moderate hypertensive patients. METHODS: Following discontinuation of previous antihypertensive treatments, and a 4-week, single-blind, placebo run-in, subjects were randomized to receive sustained-release diltiazem or propranolol. Total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and very-low-density lipoproteins (VLDL) were measured during placebo administration and after 12–16 weeks of treatment. RESULTS: No significant changes in plasma lipoprotein concentrations were noted in either the diltiazem or propranolol group compared with baseline values or each other. Marked variation in HDL, LDL, and VLDL were noted following drug treatment and in eight subjects whose lipoprotein concentrations were remeasured prior to drug treatment during the placebo period. The alterations were bidirectional, and similar in magnitude to those found following drug treatment. CONCLUSIONS: In many cases, changes in plasma lipoproteins reported to be a consequence of antihypertensive treatment may merely reflect normal intrapatient variability.

Sign in / Sign up

Export Citation Format

Share Document